Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Th2 T cell differentiation pathway describes the process by which naïve CD4+ T cells become specialized T helper 2 (Th2) cells. This differentiation is initiated by antigen presentation in the context of an IL-4-rich environment, leading to activation of STAT6 and upregulation of the master transcription factor GATA3. Th2 cells are crucial for orchestrating immune responses against extracellular parasites and are central to the pathogenesis of allergic diseases. Key effector cytokines produced by Th2 cells include IL-4, IL-5, and IL-13, which mediate B-cell help for IgE production, eosinophil recruitment, and epithelial responses. The pathway involves metabolic reprogramming and is negatively regulated by factors like IFNγ to prevent excessive Th2 polarization. Therapeutic interventions often target key cytokines or signaling molecules within this pathway to modulate allergic responses.
N/A
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Th2 T cell Differentiation Pathway (Th2 Pathway).